Dysesthesia Across Trials TRIUMPH-4 revealed dysesthesia (tingling, burning, or numbness) in 20.9% of participants at 12mg (8.8% at 9mg), versus 0.7% placebo
found that ipamorelin could stimulate the release of GH from primary rat pituitary cells and swine [9], and concluded that the peptide could be a very interesting candidate for future clinical development. A 2002 study published in the European Journal of Anatomy found that ipamorelin treatment could stimulate body weight gain and GH release in young female rats [12]
doi: 10.1182/BLOODADVANCES.2020001851
By consolidating two powerful weight-loss mechanisms into one medication, GLP-Squared eliminates the need for lipotropic add-ons for many patients while reducing injection burden and cost complexity
10.1016/j.redox.2020.101694 37
Although, anecdotally, it is no secret that Mounjaro is already being prescribed to patients without T2D for weight loss and the comorbidity of T2D and obesity blurs the line, once Mounjaro is approved I believe it will begin reducing the average out of pocket costs for these drugs